Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

Warner Chilcott29 enrolled

Overview

This study analysed and reported on the study data from three similar, risedronate studies, 1996052, 2003073, and 2003096. The objective of the study was to determine the differences in the iliac crest bone histomorphometry and bone quality in postmenopausal women who had received long term therapy with risedronate.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Osteoporosis

Interventions

risedronateDRUG

risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Completed month 36 of Study RVN-008993. * Underwent an iliac crest bone biopsy at month 36. Exclusion Criteria: * Was less than 60% compliant with regard to taking study drug from the start of the study drug to month 24 of study RVN-008993.

Locations (8)

Maria Greenwald, MD

Palm Desert, California, United States

Paul Miller, MD

Lakewood, Colorado, United States

Grattan Woodson, MD

Decatur, Georgia, United States

Christopher Recknor, MD

Gainesville, Georgia, United States

Outcomes

Primary Outcomes

Differences in iliac crest bone histomorphometry and bone quality in patients receiving risedronate

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.